May 29, 2020
Sumitovant Biopharma Announces Myovant Sciences' Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine
May 18, 2020
Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Health Company
May 15, 2020
Studies Highlight Key Relationships Between Lifestyle, Sexual Health
May 15, 2020
Lipocine Announces Presentations on TLANDO(TM) at AUA Virtual Experience 2020
May 13, 2020
Treatment Potential of LPCN 1144 Demonstrated in a Pre-Clinical NASH and Hepatic Fibrosis Model
Feb 27, 2020
Lipocine Announces Closing Of Registered Direct Offering Of Common Stock And Warrants
Feb 24, 2020
Lipocine Announces Regulatory Path Forward for TLANDO(TM) Resubmission
Dec 09, 2019
BioTE Medical Founder and Chairman Warns of Potential Serious Impact on Women's Health from Recent Position Statement on Women's Testosterone Therapy Lasting Generations
Nov 11, 2019
Lipocine Receives Complete Response Letter for TLANDO(TM) from U.S. FDA
Oct 17, 2019
New Data Demonstrates That NATESTO® Increases Serum Testosterone And Improves Symptoms While Maintaining Normal Semen Parameters In Men With Low Testosterone Through Six Months
Oct 10, 2019
Lipocine to Present at the H.C. Wainwright 3rd Annual NASH Investor Conference
Oct 01, 2019
Lipocine To Present LPCN 1144 Poster Of Distinction At The Liver Meeting® 2019
Sep 30, 2019
First Biopsy Confirmed Nash Patient Dosed In Lipocine LiFT Study Of LPCN 1144
Sep 23, 2019
Lipocine Announces Presentations at the 20th Annual Fall Meeting of the Sexual Medicine Society of North America
Sep 17, 2019
Lipocine to Present at the Ladenburg Thalmann 2019 Healthcare Conference
Sep 16, 2019
Lipocine to Participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma, Rare Disease & Gene Therapy
Aug 15, 2019
The Global Cephalosporin Drugs Market size is expected to reach $14.1 billion by 2025, rising at a market growth of 3.34% CAGR during the forecast period
Aug 07, 2019
Lipocine Announces Second Quarter 2019 Financial and Operational Results
Jul 23, 2019
Lipocine Receives FDA Clearance for Clinical Testing its NASH Candidate, LPCN 1144, in Expanded Target Population
Jul 05, 2019
Pharm Origins Research and Development Team Successfully Extracts Phtyo Testosterone